Im Cannabis Corp ( (IMCC) ) has released its Q2 earnings. Here is a breakdown of the information Im Cannabis Corp presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, leveraging a data-driven approach and a globally sourced product supply chain. In its second quarter of 2025, IM Cannabis reported a strong increase in gross profit and margin growth despite a 14% decline in revenue due to external challenges such as the ongoing conflict in Israel and supply chain delays. Key financial highlights include a 306% increase in gross profit to $3.4 million and a 371% increase in gross margin to 27%. The company also achieved an EBITDA profit of $0.1 million, a significant improvement from a loss of $2.3 million in the same quarter last year. Operating expenses remained stable with a slight increase of 2%. Looking ahead, IM Cannabis management remains optimistic about recovering the revenue impact in the coming quarters and is focused on sustainable, profitable growth as market conditions normalize.